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Abstract: Infectious laryngotracheitis virus (ILTV) is a herpes virus that causes an acute respiratory
disease of poultry known as infectious laryngotracheitis (ILT). Chicken embryo origin (CEO) and
tissue culture origin (TCO) live attenuated vaccines are routinely used for the control of ILT. However,
vaccine virus is known to revert to virulence, and it has been recently shown that ILT field viral
strains can undergo recombination with vaccinal ILTV and such recombinant ILT viruses possess
greater transmission and pathogenicity potential. Based on complete or partial genes of the ILTV
genome, few studies genotyped ILTV strains circulating in Canada, and so far, information is scarce on
whole-genome sequencing or the presence of recombination in Canadian ILTV isolates. The objective
of this study was to genetically characterize the 14 ILTV isolates that originated from three provinces
in Canada (Alberta, British Columbia and Quebec). To this end, a phylogenetic analysis of 50
ILTV complete genome sequences, including 14 sequences of Canadian origin, was carried out.
Additional phylogenetic analysis of the unique long, unique short and inverted repeat regions of
the ILTV genome was also performed. We observed that 71%, 21% and 7% of the ILTV isolates were
categorized as CEO revertant, wild-type and TCO vaccine-related, respectively. The sequences were
also analyzed for potential recombination events, which included evidence in the British Columbia
ILTV isolate. This event involved two ILTV vaccine (CEO) strains as parental strains. Recombination
analysis also identified that one ILTV isolate from Alberta as a potential parental strain for a
United States origin ILTV isolate. The positions of the possible recombination breakpoints were
identified. These results indicate that the ILTV wild-type strains can recombine with vaccinal strains
complicating vaccine-mediated control of ILT. Further studies on the pathogenicity of these ILTV
strains, including the recombinant ILTV isolate are currently ongoing.
Keywords: herpesvirus; recombination; mutation; molecular characterization; phylogenetic analysis;
poultry; vaccine
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1. Introduction
The infectious laryngotracheitis (ILT) was first reported in Canada in 1925 [1]. The causative
virus, infectious laryngotracheitis virus (ILTV), is a member of the family Herpesviridae, subfamily
alphaherpesvirinae and genus Iltovirus, known as Gallid herpesvirus-1 (GaHV-1). Peafowls and pheasants
are able to contract this virus, but chickens are considered the main host [2,3]. ILTV is an enveloped
virus with glycoprotein projections on its surface. It contains an icosahedral nucleocapsid with linear
double-stranded deoxyribonucleic acid (DNA) genome of an approximate length of 150 kilobase pairs
(kbps). The genome is comprised of a Unique Long (UL) region and a Unique Sort (US) region, flanked
by two inverted repeat regions, an internal repeat (IR) region and a terminal repeat region [4]. The ILTV
genome contains 76 open reading frames (ORFs), from which 63 are homologous to those of the herpes
simplex virus (HSV) 1, 6 are Iltovirus genus-specific, and one ORF (UL 0) is only found in the ILTV
genome [4].
ILTV is known to have tropism for the tracheal mucosa and conjunctiva, and it causes an acute
upper respiratory tract disease. Presentation of clinical signs can go from mild to severe, ranging
from nasal and eye secretions to conjunctivitis, reduced weight gain and decrease in egg production
to the most characteristic bloody mucus expectoration, gasping and death [1]. ILTV can establish
lifelong infections by establishing latency in the trachea [5] and trigeminal ganglia coinciding with the
development of the adaptive immune response [6]. Latent ILTV can be periodically reactivated when
the affected birds are exposed to stressful episodes, such as extreme weather conditions, nutritional
imbalances, transportation, the onset of laying or relocation to a new flock [7].
Control of ILT relies largely on biosecurity measures and vaccination [8]. The commonly used
vaccines for ILTV control are recombinant ILT vaccines with either herpesvirus of turkeys (HVT) or
fowlpox virus (FPV) as vectors, as well as live attenuated vaccines. Based on the method of attenuation,
attenuated vaccines can be categorized into either chicken embryo origin (CEO) or tissue culture origin
(TCO) [9]. Attenuated vaccines are usually preferred over recombinant vaccines, given the fact that
they provide fast and long-lasting protection and induce stronger cellular immunity [8]. However,
vaccine viruses present in attenuated vaccines can still go into a state of latency only to be shed later
by the infected birds. Attenuated vaccine virus is also prone to reversion to virulence by multiple
passages through bird-to-bird transmission within the flock. This event is reported more often among
CEO vaccines given the lower degree of attenuation in comparison to TCO vaccines [10–12].
Mutations are very rare in viral DNA genomes [13]; however, recombination among herpesviruses
has been well documented and is considered to be a key evolutionary strategy [14]. Recombination
can occur more frequently with the use of attenuated vaccines when coinfection with a vaccine and/or
wild-type strain takes place. Furthermore, studies have provided evidence confirming recombination
between ILTV strains [15–17], with recombination breaking points mostly identified within the UL and
IR regions of the genome [18,19]. Recombination has been reported mostly among strains related to
the CEO vaccines, resulting in new viruses with higher virulence than that of their parental strains [20].
Studies conducted in Australia [21], United States (US) [9], Italy [20], China [22] and Korea [23] have
indicated that circulating ILTV strains were genetically related to attenuated CEO vaccine viruses,
and in some cases, vaccine recombinants [24].
ILTV infection is endemic in backyard flocks in Canada, and sporadic ILT outbreaks are commonly
observed in commercial flocks [25]. CEO and TCO, as well as recombinant vaccines, are currently
available in Canada. For more than 10 years, backyard flock owners were urged to vaccinate their
birds with TCO vaccines in some of the provinces, and it is possible that backyard flocks vaccinated
with live attenuated vaccines could be infected with wild-type virus. Such situations may facilitate
co-circulation of two different ILTV strains, which could potentially enable recombination, as has been
seen in other countries [19]. Few studies have addressed the molecular nature of ILTV circulating
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in Canada using either complete or partial genes of the ILTV genome (UL 47, US 8, ORF a and
ORF b). These studies have been successful in differentiating between wild-type and vaccine-related
ILTV strains and have reported the presence of both CEO vaccine virus and wild-type ILTV in the
Canadian chicken flocks [26,27]. However, to this date, there are neither whole-genome sequences of
Canadian-origin ILTV strains nor any available information to suggest that ILTV recombination has
ever occurred in Canada. The objective of the study was to genetically characterize the ILTV isolates
obtained from ILTV clinical cases in Alberta (AB), Quebec (QC) and British Columbia (BC) through
whole-genome sequencing (WGS) as well as to provide evidence for recombination events if present in
these isolates.
2. Materials and Methods
2.1. Samples
Quantitative polymerase chain reaction (qPCR) assays targeting the ICP4 (primers,
F: 5′-GGGTCGGTTCAGTCAGTAA-3′; R: 5′-GGTCATCGACCAAAGACTGT-3′ and probe
5′-GAGGTCGACGGCCAACGC-FL-3′) and glycoprotein (g) G genes (primers, F: 5′
-ATTGCCACCGTTTCCCTAG-3′; R: 5′-CCATTTCACCTCGACTGACACT-3′ and probe,
5’-CAACCGCACCACGATTGAGG-FL-3′) have been used to quantify ILTV genome in nucleic acids of
tracheal swabs and tissues (n = 46) originated from backyard flocks of AB. A qPCR assay targeting ILTV
thymidine kinase gene (primers, F: 5′- CGA GAA CGA TGA CTC CGA CTT -3′; R: 5′- GGC CCG TCG
ACG TAA AGA -3′ and TaqMan probe, 5′-6-FAM-CGC CGC GTT GTA C-MGBNFQ-3′) has been used
to detect ILTV genome in clinical samples (n = 9) originated from commercial poultry operations in BC.
The qPCR reactions have been carried out using LC FastStart DNA Master Hybridization Probes Kit
(Roche Diagnostics, Laval, QC, Canada) or One-Step RT–PCR Master Mix (Life Technologies Inc, Austin,
TX, USA) according to manufacturers recommendation and run using LightCycler thermocycler (Roche
Diagnostics GmbH, Mannheim, State of Baden-Wurttemberg, Germany) or an Applied Biosystems
Inc (ABI) 7500 Fast Real-Time PCR unit (ABI, Foster City, CA, USA). The amplification conditions
consisted of initial denaturation of 50 ◦C for 2 min followed by denaturation of 95 ◦C for 10 min, then
40 cycles of denaturation of 95 ◦C for 15 s and annealing at 60 ◦C for 1 min. A qPCR assay targeting
gC gene (primers, F: 5′-CCTTGCGTTTGAATTTTTCTGT-3’; R: 5′-TTCGTGGGTTAGAGGTCTGT-3′
and TaqMan probe, 5′-6-FAM-CAGCTCGGTGACCCCATTCTA-BHQ1-3′) has been used to screen
clinical samples (n = 3) originated in QC commercial operations as has been described previously [28].
These ILTV-positive samples (n = 58) were obtained from the Agri Food Laboratories, Alberta
Agriculture and Forestry in Edmonton, AB, the Animal Health Center in Abbotsford, BC and
the Laboratoire de Diagnostic Moléculaire (LDM), University of Montreal, in St-Hyacinthe, QC,
respectively. In order to get enough viral DNA for WGS, the ILTV samples were propagated in either
chorioallantoic membrane (CAM) of 9- to 11-day-old specific-pathogen-free (SPF) chicken embryos
or monolayers of hepatocellular carcinoma cell lines (LMH) to increase virus titer. Only 14 of the
samples were successfully propagated and each sample required between one to three passages before
submission for WGS.
2.2. ILTV Propagation on CAM and LMH Cells
The use of embryos was approved by the Health Science Animal Care Committee (HSACC) of
the University of Calgary (Protocol number: AC19-0013). The ILTV isolates were propagated on the
CAM of SPF eggs on embryo day 10, obtained from the Canadian Food Inspection Agency (CFIA) in
Ottawa, Canada.
On viable embryonated eggs, the air cell was located by candling. A small mark was placed
in the eggshell 0.5 cm right below the bottom edge of the air cell. Carefully, while holding the
previously disinfected egg in a horizontal position, and with the previously mentioned mark looking
upwards, a puncture was made in the eggshell above the mark using a 25-gauge needle without
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introducing the needle too deep to avoid damaging the embryo. Another puncture was made in
the shell at the top of the air cell while still maintaining the egg in a horizontal position. Using a
rubber bulb covering the orifice made in the air cell, air was taken out of the air cell to create an
artificial air cell on the first puncture via negative pressure [29]. The inoculum was then deposited
in the artificial air cell and 5 days post-inoculation the CAM is collected from the eggs. CAMs were
placed in 2 milliliter (mL) tubes containing sterile zirconium beads (Benchmark Scientific, NJ, USA),
1 mL of Dulbecco’s phosphate-buffered saline (DPBS) with 1% of penicillin–streptomycin (Gibco Life
Technologies, Burlington, ON, Canada). Shortly after, the CAMs were homogenized using a microtube
homogenizer Bedbug d1030 by Benchmark Scientific. The supernatant was collected, aliquoted and
kept at −80 ◦C for further use.
For propagation of the ILTV isolates on cell monolayers, T-75 tissue culture flasks (Greiner Bio One,
Kremsmünster, Austria) precoated with 2% gelatin and containing a confluent monolayer of LMH cells
were used. Each flask contained 15 mL of Dulbecco’s Modified Eagle Medium (DMEM) containing 10%
fetal bovine serum and 1% penicillin/streptomycin (Gibco Life Technologies, Burlington, ON, Canada).
The monolayer of LMH cells was inoculated with the ILTV Canadian isolates and incubated at 37 ◦C
in 5% CO2 for 72 h. After the incubation period, flasks were submitted to three freeze- (−80 ◦C) and
thaw- (37 ◦C) cycles of 30 min each, after which cells and supernatant were collected and taken for
ultracentrifugation on a high-speed centrifuge Avanti J-26 (Beckman Coulter Life Sciences, IN, USA) at
50,000× g for three hours. After ultracentrifugation, the supernatant was discarded, and the cell pellets
were resuspended in 500 microliters (µL) of DMEM and aliquoted in small vials and stored at −80 ◦C
until further use.
2.3. Viral DNA Purification from Homogenized LMH Cells and qPCR
DNA purification was carried out using QIAmp DNA Mini Kit (QIAGEN GmbH, Hilden,
Mettmann, Germany), according to the manufacturer’s instructions, assessed for purity and quantified
using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
A quantitative PCR assay was carried out using a CFX96-c1000 Thermocycler (Bio-Rad laboratories,
Mississauga, ON, Canada) targeting the proteinase K (PK) gene, as described previously [30,31].
The total volume per reaction was 20 µL, which included 20 nanograms (ng) of genomic DNA, the Fast
SYBR Green Master Mix (Invitrogen, Burlington, ON, Canada), 10 µL of SYBR Green, 0.5 µL of forward
and reverse specific primers with a final concentration of 10 picomolar (pmol)/ µL targeting the ILTV
PK gene (F: 5′-TAC GAT GAA GCG TTC GAC TG -3′ and R: 5′-AGG CGT GAC AGT TCC AAA GT
-3′) and DNAse/RNAse-free water (Thermo Scientific, Wilmington, DE, USA). Thermocycler conditions
were 95 ◦C for 20 s for initial denaturation, then 40 cycles of denaturation to 95 ◦C for 3 s, annealing at
60 ◦C for 30 s and elongation at 95 ◦C for 10 s.
2.4. Sample Submission for WGS and Genome Reconstruction
The samples with high ILTV genomic content were directly submitted for WGS (LDM, Faculty of
Veterinary Medicine, University of Montreal, QC, Canada) and sequenced using the MiSeq platform
(Illumina Corp, San Diego, CA, USA). To remove Illumina adaptors, automatic adaptor trimming
was selected on the MiSeq spreadsheet following CLC Genomic Workbench (QIAGEN, Redwood,
CA, USA). Right before de novo assembly, another step of trimming was performed with the following
settings: minus strand only (3′ end trimming); allow internal and end matches with a minimum
internal score of 10 and a minimum end score at 4 and alignment scores cost (Mismatch cost at 2 and
Gap cost at 3).
For quality filter, settings were set at Q30 reads. Further, using CLC Genomic Workbench Quality
Trimming, with the Trim using quality scores with the limit set at 0.05, the Trim ambiguous nucleotides
with a maximum number of ambiguities set at 2 and the discard reads below 15 selected.
For genome reconstruction, all reads were mapped to a complete genome ILTV GenBank reference
(Supplementary Table S1) with the Map Reads to Reference tool in CLC Genomic Workbench, with no
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reference masking selected, match score at 1, mismatch cost at 2, linear gap cost selected, autodetect
paired distance selected, and the map randomly selected in the nonspecific match handling box.
The sequence with the most and longest reads mapped against was used as the reference to
perform the mapping of all reads with the same setting as described previously. A second mapping
was then used to obtain the consensus sequence with the Extract Consensus Sequence tool with the
options as following: low coverage definition threshold set at 5, insert N ambiguity symbols selected,
in the conflict resolution vote selected, and the use quality score checked.
Consensus sequences with the Extract Consensus Sequence tool with the options were set as
follows: Low coverage definition Threshold set at 5, Insert N ambiguity symbols selected, in the
Conflict resolution vote selected, and the Use quality score checked. Thus, the threshold was set at 5
(Supplementary Table S1).
2.5. Genotyping Based on Complete ILTV Genome
For phylogenetic analysis, the obtained sequences were aligned with ILTV sequences available
in the National Center for Biotechnology Information (NCBI) database. Sequences known to be a
product of experimental studies on recombination were not deemed necessary to fulfill the ends of
this research and hence, were not included in this study. The sequences included in this analysis
mostly comprised of field strains and live attenuated CEO and TCO vaccine sequences from different
geographic backgrounds (Supplementary Table S2). Multiple Sequence Alignment was done with Fast
Fourier Transform (MAFFT v7.450 [32]) in Geneious® v10.2.6 [33]. Sequences and alignments were
visually inspected. Sites where ambiguous nucleotides were present in the AB ILTV sequences were
replaced by the consensus sequence only in sites with no nucleotide variability in the consensus. Next,
a phylogenetic tree of the complete sequence alignment was generated using a Bayesian inference
method using MrBayes 3.2.6 [34] with default settings. It should also be mentioned that phylogenetic
analysis using maximum-likelihood resulted in very similar inferences as the Bayesian inference
method. Additional phylogenetic trees were constructed using the UL, US and IR regions of the ILTV
genome of the 50 sequences to gather key information on the presence of recombination in any of
the sequences. Posterior probability values (given as decimals) indicating the support for any given
branch are displayed as branches labels in each of the phylogenetic trees.
2.6. Recombination Analysis
Recombination analysis and detection of crossover points in the 50 aligned genome sequences
were conducted in the Recombination Detection Program (RDP4 v.4.80) [35] using default settings.
Recombination events suggested by RDP4 software were confirmed by using Similarity Plotting
(Simplot, 3.5.1, SCRoftware, Baltimore, MD, USA) [36], with a window size of 6000 and a step size
of 200.
3. Results
3.1. Flock Background Information
qPCR-confirmed ILT-positive clinical samples originated from AB belonged to small backyard
flocks, while the ILT samples originated from QC, and BC belonged to larger commercial flocks. Only
two flocks had a history of ILT vaccination: one of the flocks in QC and the other one from AB. All of the
relevant flock history and clinicopathological findings are summarized in Table 1 and Supplementary
Table S3.
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Table 1. Relevant background information of the poultry farms from which the 14 Canadian infectious
laryngotracheitis virus (ILTV) samples that yielded full genome sequences originated. Dash lines fill











# of Birds Year
#1990662 Quebec 4 days - Broiler 19,700 females No - - 2017
#2154822 Quebec 8 Ross Broiler 6400 Recombinant 3000 400 2018
#2175807 Quebec - - Broiler 17,000 No - 527 2019
#10-1122 British Columbia 11 - Layer 45,000 No - - -
#15 Alberta 6 Heritage Backyard 250 Yes ** 10 10 2014
#20 Alberta 40 Mille fleur Backyard 150 No 4 4 2015
#42 Alberta 60 Heritage Backyard 56 No 22 4 2016
#45 Alberta 24 Barnevelder Backyard 50 No 4 4 2016
#50 Alberta 10 PRS cross * Backyard 475 No 400 40 2016
#61 Alberta 96 Heritage Backyard 50 No 15 15 2017
#63 Alberta 6 Heritage mixed Backyard 150 No 5 5 2017
#77 Alberta 80 Heritage Backyard 150 No 7 4 2017
#84 Alberta 22 Heritage Backyard 50 No 5 0 2017
#85 Alberta 40 Heritage Backyard 120 No 80 80 2017
* PRS cross = Plymouth-Rhode Island-Sussex cross; ** Further details on the type of vaccine applied could not
be gathered.
3.2. ILTV Whole-Genome Sequences
Ten samples from AB, 3 samples from QC and 1 sample from BC yielded enough viral DNA and
were directly submitted for WGS (Table 2). The size of the genomes varied between 150,118–153,648 kbps,
with the smallest genome belonging to the BC isolate (CAN/BC-10-1122) due to a 3563-nucleotide
deletion on the 5′ end of its genome. Interestingly deletion was also present in TCO-like and TCO
vaccine sequences. The 14 Canadian ILTV sequences were aligned with 36 ILTV whole-genome
sequences representing various geographical areas available in the public domain, which included
TCO and CEO ILT vaccine sequences (Supplementary Table S2). The 14 Canadian ILTV sequences
were deposited in the GenBank, and their accession numbers are given in Table 2.
Table 2. Canadian ILTV full genome sequences (n = 14).





CAN/AB-15A 153,648 Alberta 5,650,374 9220 LMH cells MT797239
CAN/AB-S20 152,695 Alberta 3,630,632 18,054 LMH cells MT797240
CAN/AB-S42 153,469 Alberta 3,128,494 75,084 LMH cells MT797241
CAN/AB-S45 153,630 Alberta 4,144,190 55,821 LMH cells MT797242
CAN/AB-S50 153,641 Alberta 2,394,680 41,448 LMH cells MT797243
CAN/AB-S61 153,643 Alberta 3,603,066 15,064 LMH cells MT797244
CAN/AB-S63 152,703 Alberta 2,660,390 9072 LMH cells MT797245
CAN/AB-S77 153,633 Alberta 3,245,498 17,863 LMH cells MT797246
CAN/AB-S84 153,643 Alberta 3,090,720 9735 LMH cells MT797247
CAN/AB-T85 153,631 Alberta 2,504,122 12,822 LMH cells MT797248
CAN/BC-10-1122 150,118 British Columbia 2,404,772 502,040 LMH cells MT797249
CAN/QC-1990662 153,598 Quebec 4,669,964 67,376 CAM MT797250
CAN/QC-2154822 151,326 Quebec 4,233,878 9055 CAM MT797251
CAN/QC-2175807 153,468 Quebec 8,493,852 50,518 CAM MT797252
3.3. Phylogenetic Analysis
Using the multiple sequence alignment of the 50 full genome sequences, a phylogenetic tree
was generated. As shown in Figure 1, the first cluster mostly comprised wild-type ILTV isolates and
virulent strains considered to be different from vaccines (genotype VI–IX), 3 of the 14 Canadian ILTV
sequences clustered among this group (CAN/AB-S20, CAN/QC-2175807, CAN/AB-S63). The second
cluster grouped ILTV isolates with CEO revertant viruses (genotype V), and 10 of the 14 Canadian
ILTV sequences clustered with this group. The remaining Canadian ILTV sequence, represented
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by CAN/BC-10-1122, grouped within the cluster with the ILTV strains related to the TCO vaccines
(genotype I, II, III). Additional information is shown in Supplementary Table S4. The last cluster
included all the ILTV CEO commercial vaccine strains (Genotype IV), as well as European origin
vaccine strain Serva, Chinese strains WG, K317, LJS09, Korean strain 40,798, US strains 63,140 and
3.26.90 and Australian strains CL9 and ACC78. None of the analyzed Canadian ILTV sequences
clustered in this group.
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Of the 10 Canadian ILTV isolates clustered as CEO revertants following whole-genome sequence
analysis, it was interesting to find a high percent nucleotide identity between nine of these
sequences (CAN/QC-1990662, CAN/AB-S61, CAN/AB-S50, CAN/AB-S42, CAN/AB-T85, CAN/AB-S45,
CAN/AB-S77, CAN/AB-15A, CAN/AB-S84) and three vaccine strains: European Serva, Nobilis
Laringovac® (an attenuated ILTV Serva strain) and Poulvac ILT® (uses the ILTV Salisbury strain).
A comparative analysis was made between these nine ILTV Canadian sequences and the European Serva.
On average, these nine sequences shared 99.9% nucleotide identity with 34 SNPs inside the coding
sequence in 36 different ORFs (Table 3), including a codon insertion in ORF C, resulting in a frameshift
in the amino acid sequence. Fourteen of these SNPs are synonymous, and 20 non-synonymous. The rest
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of the Canadian sequences, CAN/QC-2175807, CAN/AB-S63, CAN/BC-10-1122, and CAN/AB-S20, did
not appear to be as closely related to the Serva strain or any of the latter mentioned vaccine strains.
Additional phylogenetic analysis was conducted using three separate portions of the ILTV genome,
the UL, US and IR regions (Figure 2a–c, respectively). Overall, the analyzed Canadian ILTV isolates
clustered similarly compared to Figure 1 results, with the exception of isolate CAN/QC-2154822, which
clustered with CEO vaccines and a US virulent strain on the IR phylogenetic tree.





(a) UL (b) US 
 
(c) IR 
Figure 2. Phylogenetic analysis of 50 ILTV sequences using the unique long region (a), unique short 
region (b) and the internal repeat regions (c) using the Bayesian inference method (MrBayes, Geneious 
software). Sequences highlighted in orange represent the Alberta ILTV isolates; in blue, the Quebec 
ILTV isolates and in purple is the ILTV isolate originated in British Columbia. Brackets and labels to 
the right of the trees separate and indicate the suggested genotype according to the clustering of the 
sequences in the phylogenetic trees. Posterior probability values are indicated as branch labels in the 
tree. 
The position within trees of sequence CAN/QC-2175807 remained constant along with 
VFAR043, J2 and Canadian CAN/AB-S63. A more detailed analysis of these sequences showed a close 
relationship among them. Between the first two mentioned strains, only 13 SNPs inside coding 
sequences differed between them, 7 of them synonymous and 6 non-synonymous. Between 
CAN/QC-2175807 and J2, only 10 SNPs inside coding sequences differed between them, 5 
synonymous and 5 non-synonymous. The same comparison was made among sequences CAN/AB-
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The position within trees of sequence CAN/QC-2175807 remained constant along with VFAR043,
J2 and Canadian CAN/AB-S63. A more detailed analysis of these sequences showed a close relationship
among them. Between the first two mentioned strains, only 13 SNPs inside coding sequences differed
between them, 7 of them synonymous and 6 non-synonymous. Between CAN/QC-2175807 and J2,
only 10 SNPs inside coding sequences differed between them, 5 synonymous and 5 non-synonymous.
The same comparison was made among sequences CAN/AB-S63, VFAR043 and J2. Between the
first two sequences, 37 SNPs inside of coding sequences could be detected, 19 synonymous and 18
non-synonymous and between CAN/AB-63 and US strain J2, only 34 SNPs, 17 synonymous and 17
non-synonymous in 13 different coding sequences (UL2, US4, UL5, US5, UL6, UL9, UL23, UL25,
UL27, UL32, UL38, UL39, UL41). CAN/QC-2154822 ILTV sequence, grouped with CEO vaccine
strains (LT BLEN, LARYNGO-VAC and CEO TRVX) and a US strain 63140/C/08/BR in the IR region
phylogenetic tree (Figure 2c), this Canadian isolate seemed to have more discrepancies with the rest
of the sequences in the alignment. Hundred and forty-four (144) SNPs were identified inside coding
sequences when compared to Serva, 21 SNPs synonymous and 123 non-synonymous, including 2
insertions, one in UL27, the other one in ORFC, and a total of 57 deletions, 36 of them concluding
on frameshifts in the amino acid sequences in 21 coding regions. However, it was with Serva and
Serva-like sequences that it was more closely related to. The Canadian ILTV isolate CAN/BC-10-1122,
which clustered among TCO vaccines in the phylogenetic tree following the whole-genome sequence
analysis, was found to cluster along with CEO vaccines in the phylogenetic trees of the US and IR
regions (Figure 2b,c), showing a nucleotide percent identity of 100% with vaccine Poulvac ILT and
Laryngo-vac vaccine sequences in the US multiple sequence alignment, and a 99.8% with Serva and
Serva-like vaccine sequences in the IR region.
Table 3. Single nucleotide polymorphisms (SNPs) of the nine Canadian ILTV sequences from the Alberta
(CAN/AB-S61, CAN/AB-S50, CAN/AB-S42, CAN/AB-T85, CAN/AB-S45, CAN/AB-S77, CAN/AB-15A,
CAN/AB-S84) and Quebec (CAN/QC-1990662) provinces using the vaccine strain Serva as a reference
sequence. Asterisks (*) represent all nine Canadian sequences. RDR = ribonucleoside-diphosphate
reductase, DUTN = deoxyuridine 5′-triphosphate nucleotidohydrolase.
Gene Protein CDS Position NucleotideChange
Amino Acid
Change Sequence
US7 Envelopeglycoprotein 57 C→ T CAN/AB-45, 84 and 77
UL39 RDR large subunit 58 G→ A D→ N CAN/AB-45, 84 and 77
UL35 Large tegumentprotein 89 C→ T T→ I CAN/AB-45, 84 and 77
UL1 Uracil-DNAglycosylase 121 C→ T D→ N
CAN/AB-15, 42, 50, 61, 84 and
CAN/QC-1990662
UL10 Envelope gM 124 T→ C T→ A *
US10 Virion protein 128 A→ G D→ G CAN/AB-45, 84 and 77
US10 128 T→ C D→ G CAN/AB-45, 84 and 77
UL1 161 T→ G Q→ P *
UL27 Envelope gB 347 A→ G V→ A *
ORFB ORF B protein 352 A→ C *
ORFA ORF A protein 360 A→ C *
UL49 Envelope gN 378 T→ C CAN/AB -15, 42, 50, 61& 84
ORFE ORF E protein 398 C→ G G→ A *
UL50 DUTN 453 A→ G *
US8 Envelope gE 629 A→ G K→ R *
UL46 Putative viraltegument protein 849 A→ G *
UL21 Tegument protein 924 C→ T CAN/AB -15, 42, 50, 61& 84
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Table 3. Cont.
Gene Protein CDS Position NucleotideChange
Amino Acid
Change Sequence
UL5 DNA replicationhelicase 1027 A→ G K→ E *
US6 Envelope gD 1164 C→ T CAN/AB-45, 84 and 77
US3 Protein Kinase 1200 A→ G *





1428 G→ C Q→ H CAN/AB -15, 42, 50, 61& 84
ORFF ORF F protein 1878 T→ C CAN/AB-15, 42, 50, 61, 84 andCAN/QC-1990662
ORFF 1883 C→ A S→ Y CAN/AB-45, 84 and 77
ORFF 1899 CT→ TA GS→ GT CAN/AB-15, 42, 50, 61, 84 andCAN/QC-1990662
UL28 Tripartite terminasesubunit 1 1913 A→ G V→ A *
UL27 Envelope gB 1931 A→ G I→ T *
UL52 Helicase-primaseprimase subunit 2232 A→ T F→ L CAN/AB -15, 42, 50, 61& 84
UL52 2256 G→ A CAN/AB -15, 42, 50, 61& 84
UL52 2325 C→ T CAN/AB -15, 42, 50, 61& 84
ICP4 Major viraltranscription factor 2342 T→ C H→ R *
ICP4 2342 A→ G H→ R *
UL36 Large tegumentprotein 2449 G→ A R→ C
CAN/AB-15, 42, 50, 61, 84 and
CAN/QC-1990662
UL36 4040 C→ T R→ H *
ICP4 Major viraltranscription factor 4281 C→ T *
ICP4 4281 G→ A *
UL36 Large tegumentprotein 7677 T→ C *
UL36 8349 C→ A CAN/AB-45, 84 and 77
3.4. Recombination Analysis
Of the 14 Canadian ILTV whole-genome sequences examined for potential recombination events,
CAN/BC-10-1122 was found to be a recombinant virus with vaccine strains as possible parental strains
(Table 4). The first suggested parent is TCO vaccine LT-IVAX®, which shared an identity of 96.3% with
the Canadian BC ILTV sequence. The analysis suggested two minor potential parents (i.e., sequences
with a minor contribution to the genome of the suggested recombinant), US-CEO origin vaccine
Poulvac ILT®, which shared 97.7% identity with the sequence CAN/BC-10-1122. CEO origin vaccine
Nobilis Laryngo-vac®, which shared 97.4% identity with the Canadian isolate. Both CEO vaccine
strains were almost identical, with 99.9% identity and only 19 nucleotide differences between them in
the coding sequence. As shown in Table 4, the detection of recombination in the CAN/BC-10-1122
isolate using various methods was highly significant with very low p values.
A second recombination event was detected in sequence 6.48.88 of US origin. In this suggested
recombination event, sequence CAN/AB-S20 was indicated as a minor parent (sequence with a minor
contribution to the genome of the suggested recombinant), and vaccine SA2 was suggested as a
potential major parent in this event (Table 4). As shown in Table 4, the detection of recombination in
6.48.88 ILTV isolate using various methods was highly significant with p values < 0.05.
Interestingly, RDP4 software pointed to another recombination event with sequence
CAN/QC-2154822 as a major parent for Australian CL9 and minor parent A20. This recombination
event had been previously described with Serva as a major parent for the CL9 isolate. After considering
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the background information on this isolate, belonging to Australia where vaccination with Serva is
done with regularity, comparing and doing a visual verification of the alignment including the QC
sequence, Serva and the rest of the isolates involved, this event was no longer taken into consideration.
Table 4. Recombination signals involving Canadian ILTV isolates, recombination analysis carried out






















2.379 × 10−6; 3.356 × 10−9 *
1.457 × 10−5; 3.362 × 10−8 *
3.060 × 10−6; 6.860 × 10−8 *
1.518 × 10−6; 3.337 × 10−8 *
1.476 × 10−5; 1.054 × 10−7 *



















* p-value attributed to recombination event including LT IVAX and Nobilis Laryngo-vac as a potential minor parent.
Both recombination events were originally revealed using RDP4 software, confirmed by RDP,
GENCONV, MaxChi, Chimaera, SiScan and 3Seq methods [37–42]. To further confirm the RDP4
analysis results, a Bootscan analysis using the full genome sequence alignment done with MAFFT
of the parental vaccine strains, suggested by RDP4 software, TCO LT-IVAX® and Poulvac ILT® was
carried out. In this analysis, the US 1874C5ILTV strain was used as a control and CAN/BC10-1122 as
the query sequence (Figure 3). Table 5 summarizes the percentage nucleotide identity of the BC ILTV
isolate (BC-10-1122) with CEO Poulvac ILT® and TCO LT-IVAX® in different segments of the ILTV
genome (1–15,393; 15,393–37,509; 37,509–113,748; 113,748–end) as indicated by bootscan analysis. It is
noteworthy to mention that the same plot was obtained when using Nobilis Laryngo-vac® as a minor
parent in the Bootscan analysis.
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Table 5. Percentages of nucleotide identity of vaccines CEO-Poulvac ILT® and TCO-LT-IVAX®with
British Columbia ILTV isolate (BC-10-1122) indicated by bootscan.
1–15,393 15,393–37,509 37,509–113,748 113,748–End
Poulvac ILT 77.09% 99.98% 99.84% 99.52%
TCO_IVAX 99.41% 99.91% 99.83% 87.99%
The bootscan analysis also corroborated the recombination event involving CAN/AB-S20 ILTV
and Australian SA2 as potential parental strains of US 6.48.88, as suggested by the RDP4 analysis;
the results are illustrated in Figure 4. In this analysis, the US-TCO strain was used as a control and
US 6.48.88 was used as the query sequence.
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4. Discussion
The aim of the current study was to genetically characterize the ILTV isolates linked to ILT-positive
cases in Canada using WGS. Among the highlights of this research was finding that most of the
obtained Canadian sequences (n = 10) are genetically related to CEO vaccines. Our observation of CEO
vaccine-related ILTV circulation in Canada is consistent with observations in other studies [1,21,43],
and more recently, coinciding with findings on a study on the molecular characterization of circulating
Western Canadian ILTV using Iltovirus specific genes, ORF a and b [26], where 84% ILTV isolates were
characterized as genotype V, CEO revertants. It is noteworthy that some of the ILTV isolates belonging
to AB and BC used in this study were also included in the previously mentioned study [26]. However,
molecular characterization using partial ORF a and b genes did not classify any of the examined
Canadian ILTV isolates as TCO vaccine-related. Instead, using partial ORF a and b genes, classified
one of the isolates in this study, BC-10-1122 (considered to be TCO vaccine-related using WGS) as
genotype IV, with the CEO vaccines, along with other two BC isolates [26].
In 1971, the BC poultry industry used three CEO attenuated vaccines for the vaccination of its
flocks against ILT. A few years later, an attenuated vaccine (TCO origin) was also introduced to be
used via eyedrop. During 1971–1973, the BC poultry industry encountered an ILT outbreak related
to attenuated vaccines that involved 25–50% of the vaccinated flocks [3]. The introduction of live
attenuated vaccines probably led to the circulation of the CEO vaccine virus in the province. The current
practice of inadequate vaccination with the TCO vaccine (for example, administering the vaccine
via drinking water, when it is indicated by the manufacturers for eyedrop administration only) may
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facilitate TCO vaccine virus reversion to virulence [12] and its circulation among the flocks in BC.
The concurrent circulation of vaccine-related ILTV strains and wild-type ILTV probably aided in the
recombination event found in the BC ILTV isolate.
In the case of AB, vaccination of commercial flocks is not a common practice, but it is done among
backyard flocks. Based on flock history data (Table 1 and Supplementary Table S3), all Alberta-derived
ILT samples in this study originated from noncommercial small back yard flocks. These flocks generally
comprise different susceptible avian species of varying ages, and new birds are frequently introduced
to the flock without adhering to proper biosecurity measures. Contact of these birds with other wild
avian species and insects [44], which could be carriers of the disease, is also likely. Along with the
transportation of show birds to various exhibitions and competitions, these set of conditions create
an ideal situation for ILTV transmission and maintenance since biosecurity in such flocks cannot be
maintained effectively [25,45].
It was also clear that Canada is not exempt from ILTV recombination events, as two of the
14 Canadian ILTV isolates (CAN/BC-10-1122 and CAN/AB-S20) appeared to be associated with
recombination, and in both cases involving the presence of CEO or TCO live attenuated vaccine viruses,
although vaccination with CEO attenuated vaccines is no longer recommended to be used in the
Western part of Canada.
Highlighted by the results from the recombination event involving Australian vaccine strain
SA2 and Canadian isolate CAN/AB-20, the results of this work are also in agreement with previous
work suggesting a US origin for the Australian vaccine strain SA2, which could have later diversified
and spread into different geographical areas [15]. This could explain its involvement in the later
mentioned recombination event with the Canadian isolate. This view is based on sequence similarity
of Canadian ILTV sequence CAN/AB-S20 with the Australian vaccine strains SA2 and A20, US field
strains 6.48.88 and S2 816 and Russian strain RU/CK/TATARSTAN/2009/1043 and pointed out by
the phylogenetic analysis results [15]. A US origin could also be the case for the Canadian isolate
CAN/AB-S20. This event could have been facilitated too by the presence of wild species of migratory
birds that could have played an important role in the spread and diversity of the viruses [7].
Similar to other viral families, recombination has been documented among different members
of the Herpesviridae family, with many of the recombination events involving the use of attenuated
vaccines [46–50]. In the case of ILTV, the attenuated CEO vaccines are usually involved in recombination
events with more frequency than the TCO vaccines, which could be influenced by the higher degree
of attenuation of the TCO vaccine strains. Recombination between attenuated ILT vaccines (either
CEO or TCO) depends on a number of factors including, but not limited to, the quantity and ratio
of the vaccines used [17]. However, naturally occurring ILTV recombination events are common,
and our results are in agreement with these studies [16,22,23]. However, we have not investigated
the consequence of these recombinant field ILTV isolates yet; it is important to know the frequency
of these recombination events and whether they lead to increased virulence, as was recorded for
other members of the Herpesviridae family such as the varicella-zoster virus (VZV) [50], HSV-1 and
HSV-2) [50], and other ILTV recombinants [16,22,23]. Future work will be required to evaluate the
pathogenicity and transmission potential of the Canadian recombinant ILTV isolates.
5. Conclusions
Using a WGS approach, we obtained the full genomes of 14 ILTVs of Canadian origin and detected
naturally occurring recombination. The CEO vaccine viruses that circulate actively within chicken
flocks in Canada added to the inadequate vaccination practices with live attenuated vaccines in some
of the provinces, could favor recombination events between vaccine and wild-type viruses, as has been
observed in the current study. Our findings add to the knowledge of ILTV evolution and challenges
the practical implications of ILT control using live attenuated vaccines.
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accession numbers for the purpose of aligning with the Canadian ILTV whole genome sequences, Table S3.
Clinicopathological history of the ILTV infected chickens where the 14 Canadian ILTV samples that yielded full
genome sequences originated, Table S4. Proposed genotype for the 14 Canadian ILTV sequences adressed in this
study, and average percent identity with the rest of the sequences belonging in the corresponding groups.
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